A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

The Company expects to start its Phase II program by the end of 2014, which will include three Phase II clinical trials of Liposomal Grb-2 salvage therapy in combination with frontline therapy in three different leukemia disease types: AML, CML and MDS.

Latest News

Mar 17, 2015
Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results

Mar 5, 2015
Letter to Shareholders from President and CEO

Feb 9, 2015
Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients

Jan 7, 2015
Bio-Path Holdings' Liposomal Grb-2 Featured in Peer-Reviewed Journal "Expert Opinion on Drug Delivery"

Jan 6, 2015
Bio-Path Holdings to Present at Biotech Showcase 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30p.m. Pacific Time

Webcast Link Here

Dec 22, 2014
Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma - Company Broadening its Pipeline with Second Product Candidate

Nov 17, 2014
Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results